Determining Cardiovascular Health Using High-Throughput Comparative Proteomics

Information

  • Research Project
  • 7536345
  • ApplicationId
    7536345
  • Core Project Number
    R44HL082382
  • Full Project Number
    2R44HL082382-02
  • Serial Number
    82382
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    9/15/2005 - 20 years ago
  • Project End Date
    9/14/2010 - 15 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    9/15/2008 - 17 years ago
  • Budget End Date
    9/14/2009 - 16 years ago
  • Fiscal Year
    2008
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/12/2008 - 17 years ago

Determining Cardiovascular Health Using High-Throughput Comparative Proteomics

[unreadable] DESCRIPTION (provided by applicant): The Phase II work proposed here involves the high-throughput proteome profiling of molecules associated with cardiovascular disease. Comparative profiling of disease-relevant species will lead to a marketable product - the PPM Cardiovascular Health and Wellness Report. Molecular profiling is accomplished using novel IMS-MS instrumentation and a three-minute analysis pioneered by PPM in Phase I work. Very short experimental timescales are required to analyze the large number of individuals necessary to obtain statistically relevant healthy and disease profiles. To accomplish this, PPM has selected a highly innovative approach in combining targeted proteomics with IMS-MS techniques. Here PPM will target low- abundance proteins using extensive abundant protein depletion as well as the immunoaffinity selection of the apolipoprotein family of proteins. It is important to note that this approach is distinguished from other immunoaffinity selection approaches in that a high-level of sample complexity is retained after sample workup. This is possible because of the reduction in spectral congestion associated with the analytical instrumentation to be used. Innovation thus lies in the marriage of the lowered-selectivity sample preparation to the instrumentation capable of managing the moderately complex sample. The end result of the comparative profiling studies is a Cardiovascular Health and Wellness Report to be provided to patients and their physicians. The significance of the Phase II work is difficult to understate. Nearly a quarter of the US population has some manifestation of cardiovascular disease. The generation of a tool that not only allows patients to track their cardiovascular health but also prompts them to do so because of its simplicity and attractiveness is highly needed. Additionally, it is important to note that PPM will extend the Cardiovascular Health and Wellness Report to a Cardiovascular Health and Wellness Plan. Here individuals would purchase a subscription to the Health and Wellness Report where they would periodically monitor their progress. During this phase of business development, the Cardiovascular Health and Wellness Report will be linked to medical information associated with proper cardiovascular care. Individuals deficient in one or more areas as determined by the Cardiovascular Health and Wellness Report would be prompted to improve their lifestyle. Achieving consumer buy-in to such health and wellness management tools has the potential to save the health care industry billions of dollars as well as reduce the human cost associated with loss of life and function. This demonstrates the importance of the Phase II work as it will determine whether or not such an impact on the general health of the population can be achieved. [unreadable] [unreadable] PUBLIC HEALTH RELEVANCE: The Phase II work will apply high-throughput, comparative proteomics for determining consensus healthy and disease proteome profiles for identified molecules. The profiles will be used to generate a Cardiovascular Health and Wellness Report to be marketed to the individual consumer. The report represents a health and wellness management tool enabling the consumer to monitor overall cardiovascular health. In the future, the report will be used in a Cardiovascular Health and Wellness plan that is tailored to the individual. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    1475837
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:1475837\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PREDICTIVE PHYSIOLOGY AND MEDICINE, INC.
  • Organization Department
  • Organization DUNS
    170945807
  • Organization City
    BLOOMINGTON
  • Organization State
    IN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    47403
  • Organization District
    UNITED STATES